Weekly Digest - May 2026
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - May 2026
29 April 2026: Tacalyx secures €11 million to advance lead TACA-targeting ADC programme toward the clinic
- Tacalyx announced the selection of its first clinical candidate, TCX-201, an antibody drug conjugate targeting tumour-associated carbohydrate antigens (TACAs), with plans to advance the program toward clinical development and file a clinical trial application in 2027
- The company also secured €11 million in a seed extension financing round from existing investors to support preclinical development of TCX-201 and advance its broader oncology pipeline
- TCX-201 is being developed for gastrointestinal malignancies and other solid tumors, leveraging Tacalyx’s proprietary platform designed to target TACAs, a novel and largely untapped class of tumor-associated antigens
- The funding will further enable progression of additional pipeline assets, with the next clinical candidate selection expected by the end of 2026, as the company transitions toward becoming a clinical-stage biotech
